Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025--Interim clinical study update to be presented in ...
2d
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback